Corresponding Author: Nicole M. Kuderer, MD, Advanced Cancer Research Group, 210 Market Street, Suite 303, Kirkland, WA 98033 (kuderern@gmail.com).
Published Online: December 10, 2020. doi:10.1001/jamaoncol.2020.5461
Author Contributions: Mr Desai and Dr Khaki contributed equally to this work.
Conflict of Interest Disclosures: Dr Khaki reported owning stock in Merck & Co and Sanofi SA within the last 2 years. Dr Kuderer reported receiving research consultant fees from G1 Therapeutics, Inc, Invitae Corporation, BeyondSpring Inc, Spectrum Pharmaceuticals, Inc, Bristol Myers Squibb, Janssen Pharmaceutica, and Total Health outside the submitted work and being a founding member of the COVID-19 and Cancer Consortium (CCC19) and former founding member of the CCC19 steering committee. No other disclosures were reported.
Funding Support: Dr Khaki was supported by training grant T32CA009515 from the National Cancer Institute.
Role of the Funder/Sponsor: The National Cancer Institute had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
2.Wang
QQ , Berger
NA , Xu
R . Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. Published online December 10, 2020.
JAMA Oncol. doi:
10.1001/jamaoncol.2020.6178Google Scholar 3.Lee
LY , Cazier
JB , Angelis
V ,
et al; UK Coronavirus Monitoring Project Team. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.
Lancet. 2020;395(10241):1919-1926. doi:
10.1016/S0140-6736(20)31173-9
PubMedGoogle ScholarCrossref